Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Industry Attractiveness - Porter’s Five Forces Analysis
4.2.1 Porter’s Five Forces Analysis for CMO
4.2.2 Porter’s Five Forces Analysis for CRO
4.3 Industry Value Chain Analysis
4.4 Industry Policies
4.5 Market Drivers
4.6 Market Restraints
4.7 Assessment of Impact of Covid-19 on the Industry


5 TECHNOLOGY SNAPSHOT
5.1 Dosage Formulation Technologies
5.2 Dosage Forms by Route of Administration
5.3 Key Considerations for Outsourcing of Pharmaceutical R&D
5.4 Major Segments in CRO – Bio Analytical Testing, Central Laboratory Testing, and cGMP Testing


6 MARKET SEGMENTATION
6.1 Service Type - CMO Segment
6.1.1 Active Pharmaceutical Ingredient (API) Manufacturing
6.1.2 Finished Dosage Formulation (FDF) Development & Manufacturing
6.1.2.1 Solid Dose Formulation
6.1.2.2 Liquid Dose Formulation
6.1.2.3 Injectable Dose Formulation
6.1.3 Secondary Packaging
6.2 Research Phase - CRO Segment
6.2.1 Pre-clinical
6.2.2 Phase I
6.2.3 Phase II
6.2.4 Phase III
6.2.5 Phase IV
6.3 Geography
6.3.1 For CMO Market Segment
6.3.1.1 North America
6.3.1.1.1 By Service Type
6.3.1.1.2 By Country
6.3.1.1.2.1 United States
6.3.1.1.2.2 Canada
6.3.1.2 Europe
6.3.1.2.1 By Service Type
6.3.1.2.2 By Country
6.3.1.2.2.1 United Kingdom
6.3.1.2.2.2 Germany
6.3.1.2.2.3 France
6.3.1.2.2.4 Italy
6.3.1.2.2.5 Rest of Europe
6.3.1.3 Asia-Pacific
6.3.1.3.1 By Service Type
6.3.1.3.2 By Country
6.3.1.3.2.1 China
6.3.1.3.2.2 India
6.3.1.3.2.3 Japan
6.3.1.3.2.4 Australia
6.3.1.3.2.5 Rest of Asia-Pacific
6.3.1.4 Latin America
6.3.1.4.1 By Service Type
6.3.1.4.2 By Country
6.3.1.4.2.1 Brazil
6.3.1.4.2.2 Mexico
6.3.1.4.2.3 Argentina
6.3.1.4.2.4 Rest of Latin America
6.3.1.5 Middle East and Africa
6.3.1.5.1 By Service Type
6.3.1.5.2 By Country
6.3.1.5.2.1 United Arab Emirates
6.3.1.5.2.2 Saudi Arabia
6.3.1.5.2.3 South Africa
6.3.1.5.2.4 Rest of Middle East and Africa
6.3.2 For CRO Segment
6.3.2.1 North America
6.3.2.2 Europe
6.3.2.3 Asia-Pacific
6.3.2.4 Latin America
6.3.2.5 Middle East and Africa


7 COMPETITIVE LANDSCAPE
7.1 Vendor Market Share Analysis
7.2 Company Profiles
7.2.1 CMO Vendors
7.2.1.1 Catalent Inc.
7.2.1.2 Recipharm AB
7.2.1.3 Jubilant Life Sciences Ltd.
7.2.1.4 Patheon Inc.
7.2.1.5 Boehringer Ingelheim Group
7.2.1.6 Pfizer CentreSource
7.2.1.7 Aenova Holding GmbH
7.2.1.8 Famar SA
7.2.1.9 Baxter Biopharma Solutions
7.2.1.10 Lonza Group
7.2.2 CRO Vendors
7.2.2.1 CMIC Holdings Co. Ltd
7.2.2.2 Covance Inc.
7.2.2.3 Syneos Health Inc.
7.2.2.4 LSK Global Pharma Service Co Ltd.
7.2.2.5 Novotech Pty Ltd.
7.2.2.6 PAREXEL International Corporation
7.2.2.7 Pharmaceutical Product Development LLC
7.2.2.8 PRA Health Sciences Inc.
7.2.2.9 Quanticate Ltd.
7.2.2.10 IQVIA Holdings Inc.
7.2.2.11 SGS SA (SGS Life Sciences)
7.2.2.12 Hangzhou Tigermed Consulting Co Ltd.
7.2.2.13 Samsung Bioepis Co. Ltd.
7.2.2.14 WuXi AppTec Inc.
7.2.2.15 Sagimet Biosciences (3V Biosciences Inc.)


8 INVESTMENT ANALYSIS


9 MARKET OPPORTUNITIES AND FUTURE TRENDS